Imfinzi (durvalumab)

pCPA File Number: 21550

Negotiation Status:

Concluded with an LOI

Indication(s):

Extensive-stage small cell lung cancer (ES-SCLC) in adult patients, first-line treatment (in combination with etoposide and either carboplatin or cisplatin)

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0234-000

pCPA Engagement Letter Issued:

2021-10-21

Negotiation Process Concluded:

2022-05-18